Tetraphase Pharmaceuticals, Inc. (TTPH)

[rusty8350]

If you scroll through their sec filings you'll see they've had multiple CTO's in the past, mostly relating, I believe, to their Master Manufacturing Services Agreement with Patheon.

Under the Master Agreement, the Company is responsible for supplying the active pharmaceutical ingredient for eravacycline to Patheon, and Patheon is responsible for manufacturing eravacycline, conducting quality control, quality assurance, analytical testing and stability testing and packaging.

But, I did go back and listen to the investors conference presentation from 9/11 again for clues today. The CEO mentioned the oral dosage program and how they were working on two different things to counter the "food effect" they believe caused negative data from that trial back in sep 2015 that led to the big drop from $50. Said they were working on both the timing of giving the drug as well as a different formulation of the oral drug. He said data should be available to present soon this quarter. During questioning at the end he sort of implied it may be what they're presenting in the next conference.

Long story short, they issued the CTO today, and they have a presentation to give on Monday 9/25. Maybe these things coincide and they present important information Monday. Maybe it's just a coincidence and the CTO has something to do with the manufacturing trade secrets regarding the makeup of Eravacycline.

Guess we will know Monday.

Little info about CTO's http://m.benzinga.com/article/8847394

Listen to referenced conference presentation here:

http://ir.tphase.com/eventdetail.cfm?EventID=184883